The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
|Podcasts|March 22, 2023
Independent Rx Forum - Five Trends in Community Pharmacy
John Beckner of National Community Pharmacists Association (NCPA) discusses how independent pharmacy plays a new role in primary care with Douglas Hoey, CEO of NCPA.
Advertisement
On this episode, John Beckner of National Community Pharmacists Association (NCPA) discusses how independent pharmacy plays a new role in primary care with Douglas Hoey, CEO of NCPA.
Advertisement
Related to this article
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5